Bacterial Vaginosis

Not in the classical sense. BV is a disruption of the vaginal microbiome, a shift away from protective Lactobacillus-dominant flora toward an overgrowth of anaerobic bacteria, rather than the direct acquisition of a specific pathogen from a partner. It can develop in people who have never had sex (though this is uncommon), and treating a partner does not always prevent recurrence in the index patient. That said, sexual activity, particularly new or multiple partners, is a strong and consistent risk factor, and female-female partners show high BV concordance. Think of BV as sexually influenced but not classically sexually transmitted.

Both cause vaginal discomfort and discharge, but the clinical fingerprints are distinct. BV produces thin, watery gray-white discharge with a characteristic fishy odor (especially after sex or menstruation), mild itch at most, and elevated vaginal pH above 4.5. A yeast infection (VVC) produces thick, clumpy white cottage-cheese discharge, intense vulvar itch and burning, no odor or a mild yeasty scent, and normal vaginal pH at or below 4.5. Because treatments are completely different, antibiotics for BV, antifungals for yeast, a clinician visit or molecular vaginal panel is the only reliable way to distinguish them. Studies show that fewer than one-third of women who self-treat for a presumed yeast infection actually have one.

The fishy odor of BV is produced by volatile amines, specifically trimethylamine, putrescine, and cadaverine, released by the anaerobic bacteria that proliferate when Lactobacillus populations decline. These amines become volatile and therefore detectable by smell only in an alkaline environment. Semen is significantly alkaline (pH ~7.2–8.0), so intercourse temporarily elevates vaginal pH and instantly intensifies amine volatilization, making the fishy odor noticeably stronger right after sex. Menstrual blood is also alkaline, explaining odor flares during periods. This chemistry is exploited in the clinical whiff test: adding potassium hydroxide (KOH) to a vaginal sample immediately releases and amplifies the amine odor, confirming BV.

Men don't develop BV themselves, they have no vaginal microbiome to disrupt, but they can harbor BV-associated bacteria (Gardnerella vaginalis and others) under the foreskin and in the urethra without symptoms. These bacteria can be reintroduced into the female partner's vaginal environment during sex, contributing to BV recurrence. A landmark 2021 randomized controlled trial (Muzny et al.) found that treating male partners with oral metronidazole plus penile-area clindamycin cream significantly reduced BV recurrence in female partners over 12 weeks, suggesting male carriage is a meaningful recurrence driver. Routine male partner treatment is not yet universally recommended in major guidelines, but clinicians increasingly discuss it for women with frequent recurrent BV.

Recurrence is the central frustration of BV management, approximately 50% of successfully treated women experience a return within 6–12 months. Leading explanations include: (1) Antibiotics suppress anaerobic overgrowth but do not restore Lactobacillus dominance: if protective flora doesn't re-establish quickly, the microbiome reverts. (2) Re-exposure to BV-associated bacteria from an untreated partner (male or female). (3) Continued douching or scented product use. (4) Individual microbiome predisposition, some women's vaginal microbiomes appear inherently less stable and prone to dysbiosis. (5) Unrecognized non-albicans species if the original diagnosis was uncertain. Extended suppressive therapy, boric acid 21 days then twice-weekly metronidazole gel 16 weeks, is the most evidence-based recurrence-reduction protocol available.

Occasionally, yes, mild BV can resolve spontaneously if the vaginal microbiome naturally rebalances. However, this is unpredictable and often takes weeks. During any period of untreated BV, you remain at substantially elevated risk for HIV and STI acquisition (~60% higher HIV risk), and in pregnancy, untreated BV can cause preterm labor. If you have symptoms, are pregnant, or are about to have a gynecologic procedure, do not wait it out, a short antibiotic course resolves it quickly and removes downstream risk. Given the high asymptomatic rate, getting tested is more valuable than watching and waiting.

Yes, BV during pregnancy is associated with preterm labor, premature rupture of membranes, low birth weight, and postpartum endometritis (uterine infection after delivery). BV-associated bacteria produce enzymes that degrade cervical mucus and amniotic membranes, potentially triggering inflammatory pathways involved in preterm labor. Symptomatic pregnant people are treated with antibiotics regardless of trimester. Oral metronidazole is considered safe throughout pregnancy, including the first trimester. Vaginal clindamycin cream is avoided after 22 weeks due to rare associations with adverse neonatal outcomes; oral clindamycin is used instead when metronidazole is not tolerated. If you notice any abnormal discharge or vaginal odor during pregnancy, contact your OB or midwife promptly.

Yes: boric acid 600 mg vaginal suppositories play an evidence-based role in recurrent BV management, primarily as an adjunct to (not replacement for) antibiotics. Boric acid lowers vaginal pH directly, creating an acidic environment that suppresses anaerobic growth and supports Lactobacillus reestablishment. A validated recurrence-reduction protocol uses boric acid daily for 21 days following completion of the acute antibiotic course, then twice-weekly metronidazole vaginal gel for 16 weeks, with clinical trial data supporting meaningful recurrence reduction. Boric acid alone does not adequately treat an active acute BV episode. It is also NOT safe during pregnancy (embryotoxic: do not use at any trimester), is for intravaginal use only (oral ingestion is toxic), and is not FDA-approved for BV but is recommended in several clinical guideline addenda. Use only pharmaceutical-grade vaginal suppositories, not DIY preparations.

BV is diagnosed by three main methods. Amsel criteria (standard in primary care): four signs assessed together: (1) thin, gray-white homogeneous discharge; (2) vaginal pH above 4.5; (3) a positive whiff test (fishy amine odor when potassium hydroxide is added to the sample); (4) clue cells on saline wet-mount microscopy (vaginal epithelial cells whose borders appear stippled and indistinct, coated with adherent bacteria). Three of four positive findings confirms BV. Nugent score (research standard): a Gram-stained vaginal smear scored 0–10 based on the balance of Lactobacillus versus anaerobic morphotypes; 7–10 = BV. Molecular NAAT panel (highest accuracy): detects BV-associated bacteria and Lactobacillus depletion pattern from a single swab; available at most private labs and as at-home kits, no pelvic exam required for self-collected swabs.

BV is treated with antibiotics. The CDC's 2021 STI Treatment Guidelines recommend three equivalent first-line options: (1) Metronidazole 500 mg orally twice daily for 7 days, the most extensively studied regimen; avoid alcohol during and 24 hours after. (2) Metronidazole 0.75% vaginal gel, one applicator once daily for 5 days: equivalent efficacy, lower systemic absorption, fewer systemic side effects. (3) Clindamycin 2% vaginal cream, one applicator nightly for 7 days, alternative for metronidazole intolerance; note that clindamycin cream is oil-based and degrades latex condoms for 5 days after use. Alternative single-dose option: secnidazole 2 g granules orally. Cure rates at one week: 70–80% for all regimens. Complete the full course even if symptoms improve early. Recurrence affects ~50% within a year, ask your clinician about suppressive therapy if this is not your first episode.

Yes, substantially. BV disrupts the acidic, Lactobacillus-rich environment that serves as the vagina's chemical barrier against pathogens. People with active BV are an estimated 60% more likely to acquire HIV from an HIV-positive partner, and are at meaningfully elevated risk for herpes simplex virus, gonorrhea, chlamydia, HPV, and trichomoniasis. The mechanism is twofold: elevated vaginal pH makes pathogens more viable, and depleted Lactobacillus eliminates natural hydrogen peroxide and lactic acid production that inhibits many STI pathogens directly. Treating BV promptly and staying current with STI screening substantially lowers this compounded risk.

CDC and NHANES data consistently show BV prevalence approximately twice as high among Black women (~50%) compared to white women (~23%), with Hispanic women showing intermediate rates, a disparity that has been documented for over two decades. Research consistently attributes this to structural and social factors, not biological differences or individual behavior: unequal access to routine gynecologic care means BV goes undetected longer; reduced ability to access timely treatment means untreated episodes persist; chronic stress from structural racism and discrimination has documented effects on immune function and vaginal microbiome stability (allostatic load); and historical medical mistrust, rooted in documented ethical failures in U.S. medical history, reduces healthcare engagement. Expanding access to low-cost or free vaginal NAAT panels, telehealth prescription services, and at-home testing directly addresses this disparity.

Yes: douching is one of the strongest documented risk factors for BV, associated with approximately double the BV risk in prospective studies. Douching washes out the protective Lactobacillus-dominant flora, raises vaginal pH, and strips the natural defense mechanisms that keep anaerobic bacteria in check, sometimes precipitating a BV episode within days of a single douche. The vagina is entirely self-cleaning through natural secretions that maintain its acidic, healthy microbiome without external intervention. For external hygiene: warm water on the outer vulva is all that is needed or beneficial. Scented soaps, feminine washes, bubble baths, and intimate sprays applied near the vaginal opening have similar disrupting effects and should be avoided.